Study Backs Merck's Ervebo for Bundibugyo Ebola
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- A new study in the New England Journal of Medicine led by Edouard Lhomme of the University of Bordeaux adds to a growing body of evidence that Merck's Ervebo vaccine, licensed for Zaire ebolavirus, triggers antibodies that may cross-protect against the Bundibugyo species.
- The DRC outbreak is the third largest on record and the fastest-growing ever, with nearly 2,500 confirmed cases and close to 1,000 deaths as of Monday, concentrated in the northeast where a 2018-2020 Zaire outbreak killed thousands and saw 300,000+ people vaccinated with Ervebo.
- The WHO's Strategic Advisory Group of Experts on Immunization will study whether Ervebo should be tested in the outbreak zone at its early October meeting; WHO has so far expressed only "lukewarm support," prioritizing Bundibugyo-specific vaccines that remain months from field trials.
- Africa CDC and Doctors Without Borders are planning a clinical trial of a two-dose vaccine regimen in health workers, per Bloomberg; IAVI said it intends to supply doses of its investigational Sudan virus vaccine for the study if partners and DRC authorities align.
- A Lancet commentary by noted DRC Ebola expert Jean-Jacques Muyembe-Tamfum and colleagues cited striking observational data: of 1,000 confirmed cases with known vaccination status, the 9 who had received Ervebo in the earlier outbreak all survived, and none of 242 fatal cases had been previously vaccinated.
- An unpublished cluster of 8 healthcare workers who operated on a pregnant woman later identified as Ebola-infected showed stark outcomes: the 3 who had been previously vaccinated survived, while all 5 unvaccinated workers died.
- Modeling by Isaac Bogoch of the University of Toronto warned ring vaccination may underperform in this outbreak because two-thirds of confirmed deaths were people who never sought care and were only tested post-mortem, making contact tracing highly challenging.
- WHO concerns include that lab cross-protection signals may not translate to real-world benefit, that deploying Ervebo could create a "false sense of security" among responders, and that breakthrough infections could damage public confidence in Ebola vaccines for future outbreaks.
Why it matters: With no licensed Bundibugyo vaccine likely ready for field trials for months and nearly 1,000 already dead in the DRC's fastest-growing Ebola outbreak, the WHO's SAGE committee faces a high-stakes decision at its early October meeting on whether to greenlight clinical testing of the 500,000 Ervebo doses sitting in the UNICEF-controlled stockpile. The Lancet's observational signal — 9 prior Ervebo recipients survived, 0 of 242 deaths had been vaccinated — is suggestive but not proof, and deploying an unproven cross-protective vaccine risks both wasting scarce doses and eroding trust if breakthrough infections follow.
Ask SkimNews
